These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35460360)

  • 1. An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells.
    Mansour OC; Nudelman A; Rephaeli A; Phillips DR; Cutts SM; Evison BJ
    Cancer Chemother Pharmacol; 2022 Jun; 89(6):773-784. PubMed ID: 35460360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent.
    Evison BJ; Mansour OC; Menta E; Phillips DR; Cutts SM
    Nucleic Acids Res; 2007; 35(11):3581-9. PubMed ID: 17483512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets.
    Evison BJ; Chiu F; Pezzoni G; Phillips DR; Cutts SM
    Mol Pharmacol; 2008 Jul; 74(1):184-94. PubMed ID: 18413664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance.
    Cutts SM; Nudelman A; Pillay V; Spencer DM; Levovich I; Rephaeli A; Phillips DR
    Oncol Res; 2005; 15(4):199-213. PubMed ID: 17822280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
    Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent.
    Cutts SM; Rephaeli A; Nudelman A; Ugarenko M; Phillips DR
    Curr Top Med Chem; 2015; 15(14):1409-22. PubMed ID: 25866273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.
    Mansour OC; Evison BJ; Sleebs BE; Watson KG; Nudelman A; Rephaeli A; Buck DP; Collins JG; Bilardi RA; Phillips DR; Cutts SM
    J Med Chem; 2010 Oct; 53(19):6851-66. PubMed ID: 20860366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
    Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
    J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
    Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
    Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of pixantrone in the treatment of non-Hodgkin's lymphoma.
    Borchmann P; Schnell R
    Expert Opin Investig Drugs; 2005 Aug; 14(8):1055-61. PubMed ID: 16050797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity.
    Evison BJ; Bilardi RA; Chiu FC; Pezzoni G; Phillips DR; Cutts SM
    Nucleic Acids Res; 2009 Oct; 37(19):6355-70. PubMed ID: 19720735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).
    Cutts SM; Rephaeli A; Nudelman A; Hmelnitsky I; Phillips DR
    Cancer Res; 2001 Nov; 61(22):8194-202. PubMed ID: 11719450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate.
    Cutts SM; Swift LP; Pillay V; Forrest RA; Nudelman A; Rephaeli A; Phillips DR
    Mol Cancer Ther; 2007 Apr; 6(4):1450-9. PubMed ID: 17431124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions.
    Beeharry N; Di Rora AG; Smith MR; Yen TJ
    Cancer Biol Ther; 2015; 16(9):1397-406. PubMed ID: 26177126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and DNA sequence selectivity of formaldehyde-mediated DNA-adducts of the novel N-(4-aminobutyl) acridine-4-carboxamide.
    Ankers EA; Evison BJ; Phillips DR; Brownlee RTC; Cutts SM
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5710-5715. PubMed ID: 25453806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pixantrone maleate for non-Hodgkin's lymphoma.
    Mukherji D; Pettengell R
    Drugs Today (Barc); 2009 Nov; 45(11):797-805. PubMed ID: 20126672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde.
    Cutts SM; Swift LP; Rephaeli A; Nudelman A; Phillips DR
    Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):431-47. PubMed ID: 16178771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.
    Péan E; Flores B; Hudson I; Sjöberg J; Dunder K; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2013; 18(5):625-33. PubMed ID: 23615696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features.
    Pumuye PP; Evison BJ; Konda SK; Collins JG; Kelso C; Medan J; Sleebs BE; Watson K; Phillips DR; Cutts SM
    Bioorg Med Chem; 2020 Feb; 28(3):115260. PubMed ID: 31870833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The power and potential of doxorubicin-DNA adducts.
    Cutts SM; Nudelman A; Rephaeli A; Phillips DR
    IUBMB Life; 2005 Feb; 57(2):73-81. PubMed ID: 16036566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.